ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Genomic Evolution after Chemoradiotherapy in Anal Squamous Cell Carcinoma.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 49 citations in OpenAlex.
- Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.Journal for immunotherapy of cancer · 2024Trial
- Overcoming Drug Resistance by Paclitaxel Resistance in Triple-Negative Breast Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Emerging advances and future opportunities in the molecular and therapeutic landscape of anal cancer.Nature reviews. Clinical oncology · 2025Review
- Elucidating DNA Damage-Dependent Immune System Activation.International journal of molecular sciences · 2025Review
- The role of HR-HPV integration in the progression of premalignant lesions into different cancer types.Heliyon · 2024Review
- Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?Pharmaceuticals (Basel, Switzerland) · 2024Review
- Human Papillomavirus-Induced Chromosomal Instability and Aneuploidy in Squamous Cell Cancers.Viruses · 2024Review
- Unraveling Emerging Anal Cancer Clinical Biomarkers from Current Immuno-Oncogenomics Advances.Molecular diagnosis & therapy · 2024Review
- RNA-seq analysis identifies transcriptomic profiles associated with anal cancer recurrence among people living with HIV.Annals of medicine · 2023Article
- PTPRD/PTPRT mutation correlates to treatment outcomes of immunotherapy and immune landscape in pan-cancers.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Genomic mapping of metastatic organotropism in lung adenocarcinoma.Cancer cell · 2023Article
- Site of analysis matters - Ongoing complete response to Nivolumab in a patient with HIV/HPV related metastatic anal cancer andOncotarget · 2022Article
- Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.Frontiers in oncology · 2022Article
- Associations of HER2 Mutation With Immune-Related Features and Immunotherapy Outcomes in Solid Tumors.Frontiers in immunology · 2022Article
- Molecular and genomic characterisation of a panel of human anal cancer cell lines.Cell death & disease · 2021Article
- Genomic Landscape of Primary and Recurrent Anal Squamous Cell Carcinomas in Relation to HPV Integration, Copy-Number Variation, and DNA Damage Response Genes.Molecular cancer research : MCR · 2021Article
- A frequent nonsense mutation in exon 1 across certain HLA-A and -B alleles in leukocytes of patients with acquired aplastic anemia.Haematologica · 2021Article
- Molecular and immunophenotypic characterization of anal squamous cell carcinoma reveals distinct clinicopathologic groups associated with HPV and TP53 mutation status.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2021Article
- Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer.Cancers · 2021Review
- Beyond Tumor Mutation Burden: Tumor Neoantigen Burden as a Biomarker for Immunotherapy and Other Types of Therapy.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 2 institutions in 1 country.
Kent W MouwDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
James M ClearyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Brendan ReardonDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jonathan PikeDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Lior Z BraunsteinDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jaegil KimBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Ali Amin-MansourDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Diana MiaoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Alexis DamishDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Joanna ChinDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts.
Patrick A OttDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Charles S FuchsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Neil E MartinDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Scott CarterBroad Institute of MIT and Harvard, Cambridge, Massachusetts.
Harvey J MamonDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts.
Jason L HornickDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. alan_dandrea@dfci.harvard.edu eliezerm_vanallen@dfci.harvard.edu.
Alan D D'AndreaDepartment of Radiation Oncology, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, Massachusetts. alan_dandrea@dfci.harvard.edu eliezerm_vanallen@dfci.harvard.edu.
Dana-Farber Cancer Institute · USBrigham and Women's Hospital · US
Funding
Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MTissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MResistance to Emerging Androgen Deprivation Therapies in Prostate CancerK08CA188615 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2014 to 2017
$708kNCATS NIH HHS UL1 TR001102NCATS NIH HHS UL1 TR001863NCI NIH HHS K08 CA188615NCI NIH HHS P50 CA127003
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdultAgedAged, 80 and overAnus NeoplasmsCarcinoma, Squamous CellChemoradiotherapyClass I Phosphatidylinositol 3-KinasesDisease-Free SurvivalDrug Resistance, NeoplasmEvolution, MolecularF-Box-WD Repeat-Containing Protein 7FemaleGenome, HumanHumansMaleMiddle AgedClass I Phosphatidylinositol 3-KinasesF-Box-WD Repeat-Containing Protein 7FBXW7 protein, humanPIK3CA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.